BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 20658437)

  • 1. Mechanisms of diabetic nephropathy--old buddies and newcomers part 2.
    Nawroth PP; Isermann B
    Exp Clin Endocrinol Diabetes; 2010 Nov; 118(10):667-72. PubMed ID: 20658437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of diabetic nephropathy--old buddies and newcomers part 1.
    Nawroth PP; Isermann B
    Exp Clin Endocrinol Diabetes; 2010 Oct; 118(9):571-6. PubMed ID: 20658438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted therapies in diabetic nephropathy: an update.
    Gupta A; Gupta P; Biyani M
    J Nephrol; 2011; 24(6):686-95. PubMed ID: 22058027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathophysiology of diabetic nephropathy: involvement of multifaceted signalling mechanism.
    Balakumar P; Arora MK; Reddy J; Anand-Srivastava MB
    J Cardiovasc Pharmacol; 2009 Aug; 54(2):129-38. PubMed ID: 19528810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Potential therapeutic targets for diabetic nephropathy].
    Makino Y; Haneda M
    Nihon Rinsho; 2009 Aug; 67(8):1627-35. PubMed ID: 19768953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy.
    Arora MK; Reddy K; Balakumar P
    Eur J Pharmacol; 2010 Jun; 636(1-3):137-44. PubMed ID: 20347778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats.
    Lloberas N; Cruzado JM; Franquesa M; Herrero-Fresneda I; Torras J; Alperovich G; Rama I; Vidal A; GrinyĆ³ JM
    J Am Soc Nephrol; 2006 May; 17(5):1395-404. PubMed ID: 16597691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Podocyte hypertrophy in diabetic nephropathy.
    Kim NH
    Nephrology (Carlton); 2005 Oct; 10 Suppl():S14-6. PubMed ID: 16174280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The renal hemodynamic basis of diabetic nephropathy.
    O'Bryan GT; Hostetter TH
    Semin Nephrol; 1997 Mar; 17(2):93-100. PubMed ID: 9148381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The renin-angiotensin system and diabetic nephropathy.
    Gurley SB; Coffman TM
    Semin Nephrol; 2007 Mar; 27(2):144-52. PubMed ID: 17418683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression of diabetic nephropathy in type 1 diabetic patients.
    Najafian B; Mauer M
    Diabetes Res Clin Pract; 2009 Jan; 83(1):1-8. PubMed ID: 19070384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug discovery for diabetic nephropathy: trying the leap from mouse to man.
    Breyer MD
    Semin Nephrol; 2012 Sep; 32(5):445-51. PubMed ID: 23062985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies of cardiovascular and renal function in subclinical and manifest diabetic nephropathy.
    Berglund J
    Acta Med Scand Suppl; 1988; 722():1-69. PubMed ID: 3163465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Physiopathology of diabetic nephropathy: what we learn from transplantation].
    Pirson Y
    Nephrologie; 1998; 19(3):105-9. PubMed ID: 9633051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular mechanisms in the pathogenesis of diabetic nephropathy: an update.
    Arora MK; Singh UK
    Vascul Pharmacol; 2013 Apr; 58(4):259-71. PubMed ID: 23313806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldose reductase inhibitors and diabetic kidney disease.
    Oates PJ
    Curr Opin Investig Drugs; 2010 Apr; 11(4):402-17. PubMed ID: 20336588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Toll-like receptors in diabetic nephropathy.
    Mudaliar H; Pollock C; Panchapakesan U
    Clin Sci (Lond); 2014 May; 126(10):685-94. PubMed ID: 24490813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of aspirin on experimental diabetic nephropathy.
    Moel DI; Safirstein RL; McEvoy RC; Hsueh W
    J Lab Clin Med; 1987 Sep; 110(3):300-7. PubMed ID: 3475395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging drugs for diabetic nephropathy.
    Bruno S; Cattaneo D; Perico N; Remuzzi G
    Expert Opin Emerg Drugs; 2005 Nov; 10(4):747-71. PubMed ID: 16262561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of non-coding RNAs in diabetic nephropathy: potential applications as biomarkers for disease development and progression.
    Alvarez ML; Distefano JK
    Diabetes Res Clin Pract; 2013 Jan; 99(1):1-11. PubMed ID: 23102915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.